Corebridge Financial today announced the addition of Protected Growth Benefit and preset allocation options to select versions of The Power Series of Index Annuities®, enhancing the accumulation and diversification capabilities of the company’s index annuity lineup.
Corebridge research found that protecting and growing retirement savings are both key goals for pre-retirees ages 45+, with 73% saying it is very important to make sure their retirement nest egg does not decline in retirement and 72% saying it is very important to continue growing it.1 The findings highlight the value of solutions that balance multiple financial objectives, and diversification can help support that approach.
“Product innovation is at its best when it improves how customers achieve their financial goals, and our latest index annuity enhancements are designed to do exactly that by helping retirement savers grow and protect their assets with greater confidence,” said Bryan Pinsky, President of Individual Retirement and Life Insurance at Corebridge Financial. “The Protected Growth Benefit adds another layer of accumulation support through a guaranteed increase in contract value, and preset allocation options make diversification easier through ready-made strategy blends.”
Protected Growth Benefit
Index annuities offer opportunities for growth tied to market index performance while guaranteeing that principal will never decline due to market volatility.2 The Protected Growth Benefit builds on that foundation by adding a guaranteed level of contract value growth that can help customers pursue their long-term financial goals even in weak or flat market conditions.
Specifically, Protected Growth provides a guaranteed minimum accumulation benefit at the end of the withdrawal charge period. The current Protected Growth Benefit rate for contracts with a 7-year withdrawal charge period is 26.25%. For example, if a contract with a $100,000 premium and a 7-year withdrawal charge period earns less than $26,250 in credited interest over seven years, the contract value would be adjusted to $126,250.3
The Protected Growth Benefit is available in select products within The Power Series of Index Annuities family.4 While there are no fees for this optional product feature, interest crediting rates are lower when Protected Growth is elected.
Preset Allocation Options
Preset allocation options offer simplified access to diversification within a single annuity. Customers can select from ready-made strategy blends – U.S. Stability, Global Stability, Balanced, U.S. Growth and Global Growth – designed to support different objectives and preferences.
The options draw from a range of index strategies, including the S&P 500®, Russell 2000®, PIMCO Global Optima Index®, MSCI EAFE, ML Strategic Balanced Index® and Franklin Quality Dividend. By combining multiple strategies, preset allocation options help customers participate in growth opportunities while managing risk across different market environments.
Preset allocation options are available in select products within The Power Series of Index Annuities family.5 There are no fees associated with this product feature.
For more information about The Power Series of Index Annuities and the broader range of annuity solutions available from Corebridge, visit What We Offer on corebridgefinancial.com.
Important information on The Power Series of Index Annuities
Neither asset allocation nor diversification ensure a profit or protect against market loss.
Index annuities are not a direct investment in the stock market. They are long-term insurance products with guarantees backed by the claims-paying ability of the issuing insurance company. They provide the potential for interest to be credited based in part on the performance of the specified index, without the risk of loss of premium due to market downturns or fluctuations. Index annuities may not be appropriate for all individuals.
Withdrawals may be subject to federal and/or state income taxes. An additional 10% federal tax may apply if you make withdrawals or surrender your annuity before age 59½. Consult your tax advisor regarding your specific situation.
Index interest accounts are not a permanent part of the contract and may be removed due to circumstances beyond the control of American General Life Insurance Company. Such circumstances include, but are not limited to, the discontinuation of an index, a change in the composition or calculation of an index, the inability to license the use of an index and the inability to hedge risks associated with these index interest accounts. Special rules govern how assets in a discontinued index interest account may be reallocated. These rules may differ by state. Please see the Owner Acknowledgment and Disclosure Statement for more information.
All contract and optional benefit guarantees, including any fixed account crediting rates or annuity rates, are backed by the claims-paying ability of the issuing insurance company. They are not obligations of or backed by the distributor, insurance agency or any affiliates of those entities and none makes any representations or guarantees regarding the claims-paying ability of the issuing insurance company.
This material is general in nature, was developed for educational use only, and is not intended to provide financial, legal, fiduciary, accounting or tax advice, nor is it intended to make any recommendations. Applicable laws and regulations are complex and subject to change. Please consult with your financial professional regarding your situation. For legal, accounting or tax advice consult the appropriate professional.
Annuities are issued by American General Life Insurance Company (AGL), Houston, Texas. Power Series Modified Single Premium Deferred Fixed Index Annuity. Contract numbers: AG-800 (12/12), AG-800-ID (12/12) and AG-801 (12/12).
American General Life Insurance Company (AGL) is a member of Corebridge Financial, Inc. The underwriting risks, financial and contractual obligations and support functions associated with the annuities issued by AGL are its responsibility. AGL does not solicit, issue or deliver policies or contracts in the state of New York. Annuities and riders may vary by state and are not available in all states. This material is not intended for use in the state of New York.
Important information on the indices
Indices are unmanaged, have no identifiable objectives and cannot be purchased. Performance of indices do not reflect the deduction of any fees and charges.
The S&P 500® is an equity index that tracks the performance of 500 of the largest companies in the U.S. It is a product of S&P Dow Jones Indices LLC (“SPDJI”), and has been licensed for use by American General Life Insurance Company (“AGL”) and affiliates. Standard & Poor’s®, S&P®, and S&P 500® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by AGL and affiliates. AGL and affiliates’ products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or their respective affiliates, and none of such parties make any representation regarding the advisability of purchasing such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P 500® Index.
The Russell 2000® is an equity index that tracks the performance of small-cap stocks in the U.S. The index annuity product to which this disclosure applies (the “Product”) has been developed solely by American General Life Insurance Company (“AGL”). The Product is not in any way connected to or sponsored, endorsed, sold or promoted by the London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). FTSE Russell is a trading name of certain of the LSE Group companies.
All rights in the Russell 2000® Index (the “Index”) vest in the relevant LSE Group company which owns the Index. Russell®, Russell 2000®, and FTSE Russell® are trademark(s) of the relevant LSE Group companies and are used by any other LSE Group company under license. TMX® is a trademark of TSX, Inc. and used by the LSE Group under license. The Index is calculated by or on behalf of FTSE International Limited or its affiliate, agent or partner. The LSE Group does not accept any liability whatsoever to any person arising out of (a) the use of, reliance on or any error in the Index or (b) the purchase of or operation of the Product. The LSE Group makes no claim, prediction, warranty or representation either as to the results to be obtained from the Product or the suitability of the Index for the purpose to which it is being put by AGL.
The PIMCO Global Optima Index® (the “Index”) is a comprehensive equity and bond index, offering exposure to global equity and U.S. fixed income markets. The Index is a trademark of Pacific Investment Management Company LLC (“PIMCO”) and has been licensed for use by American General Life Insurance Company (“AGL”) with the Power Series of Index Annuities (the “Product”). The Index is the exclusive property of PIMCO and is made and compiled without regard to the needs including, but not limited to, the suitability or appropriateness needs, as applicable, of AGL, the Product, or owners of the Product. The Product is not sold, sponsored, endorsed or promoted by PIMCO or any other party involved in, or related to, making or compiling the Index. Neither PIMCO, the index calculation agent nor any of the constituent owners provides investment advice to AGL with respect to the Product or to owners of the Product.
Neither PIMCO nor any other party involved in, or related to, making or compiling the Index has any obligation to continue to provide the Index to AGL with respect to the Product. Neither PIMCO nor any other party involved in, or related to, making or compiling the Index makes any representation regarding the Index, Index information, performance, annuities generally or the Product particularly.
PIMCO disclaims all warranties, express or implied, including all warranties of merchantability or fitness for a particular purpose or use. PIMCO shall have no responsibility or liability whatsoever with respect to the Product. The Index is comprised of a number of constituents, some of which are owned by entities other than PIMCO. The Index relies on a variety of publicly available data and information and licensable equity and fixed income sub-indices. All disclaimers relative to PIMCO also apply separately to those constituent owners and to the index calculation agent.
The MSCI EAFE is an international equity index that tracks the performance of large- and mid-cap stocks from developed markets around the world, excluding the U.S. and Canada. The product referred to herein is not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such product or any index on which such product is based. The contract contains a more detailed description of the limited relationship MSCI has with Licensee and any related product.
The ML Strategic Balanced Index® is a hybrid index that seeks growth and risk management by actively allocating to equities, fixed income and cash. It embeds an annual index cost in the calculations of the change in index value over the index term. This “embedded index cost” will reduce any change in index value over the index term that would otherwise have been used in the calculation of index interest, and it funds certain operational and licensing costs for the index. It is not a fee paid by you or received by American General Life Insurance Company (“AGL”). AGL’s licensing relationship with Merrill Lynch, Pierce, Fenner & Smith Incorporated for use of the ML Strategic Balanced Index® and for use of certain service marks includes AGL’s purchase of financial instruments for purposes of meeting its interest crediting obligations. Some portion of those instruments will, or may be, purchased from Merrill Lynch, Pierce, Fenner & Smith Incorporated or its affiliates.
Merrill Lynch, Pierce, Fenner & Smith Incorporated and its affiliates (“BofA Merrill Lynch”) indices and related information, the name “BofA Merrill Lynch”, and related trademarks, are intellectual property licensed from BofA Merrill Lynch, and may not be copied, used, or distributed without BofA Merrill Lynch’s prior written approval. The products of licensee AGL have not been passed on as to their legality or suitability, and are not regulated, issued, endorsed, sold, guaranteed, or promoted by BofA Merrill Lynch. BOFA MERRILL LYNCH MAKES NO WARRANTIES AND BEARS NO LIABILITY WITH RESPECT TO ANY INDEX, ANY RELATED INFORMATION, ITS TRADEMARKS, OR THE PRODUCT(S) (INCLUDING WITHOUT LIMITATION, ITS QUALITY, ACCURACY, SUITABILITY AND/OR COMPLETENESS).
The ML Strategic Balanced Index® (the “Index”) is the property of Merrill Lynch, Pierce, Fenner & Smith Incorporated, which has contracted with S&P Opco, LLC (a subsidiary of S&P Dow Jones Indices LLC) to calculate and maintain the Index. The Index is not sponsored by S&P Dow Jones Indices or its affiliates or its third party licensors (collectively, “S&P Dow Jones Indices”). S&P Dow Jones Indices will not be liable for any errors or omissions in calculating the Index. “Calculated by S&P Dow Jones Indices” and the related stylized mark(s) are service marks of S&P Dow Jones Indices and have been licensed for use by Merrill Lynch, Pierce, Fenner & Smith Incorporated.
The Franklin Quality Dividend (“FQD”) Index is a hybrid index that seeks steady growth by combining two types of U.S. dividend-paying stocks and cash. It has been developed and is owned solely by QS Investors LLC, a subsidiary of Franklin Resources, Inc. Neither BlackRock (the sponsor of iShares ETFs) nor Invesco is affiliated with Franklin Resources, Inc. and QS Investors, LLC. FQD and any security or product based on or making use of FQD are not sponsored, endorsed, or promoted by BlackRock or Invesco, and neither company bears any responsibility or liability for or with respect to FQD or any security or product based on or making use of FQD.
FQD is calculated on behalf of QS Investors, LLC by Solactive or its affiliate, agent or partner. Solactive, QS Investors, LLC, Franklin Resources, Inc. and their respective affiliates do not make any claim, prediction, warranty or representation as to the accuracy and completeness of FQD, the results to be obtained from use of FQD or the suitability of FQD for the purpose to which it is being put by American General Life Insurance Company, and bear no liability for FQD or for any security or product based on or making use of FQD. FQD embeds an annual index cost in the calculations of the change in index value. This embedded index cost will reduce any change in index value, and it funds certain operational and licensing costs for the Index. Since it will affect the return of the Index, it may also impact the amount of interest credited to an index annuity; however, it is not a fee paid by the policy owner or received by the issuing insurance company.
About Corebridge Financial
Corebridge Financial, Inc. (NYSE: CRBG) makes it possible for more people to take action in their financial lives. With more than $380 billion in assets under management and administration as of March 31, 2026, Corebridge Financial is one of the largest providers of retirement solutions and insurance products in the United States. We proudly partner with financial professionals and institutions to help individuals plan, save for and achieve secure financial futures. For more information, visit corebridgefinancial.com and follow us onLinkedIn.
1 Corebridge Financial, Decumulation Planning Gap Study, June 2026.
2 Index annuities are not a direct investment in the stock market. Interest earned is never less than zero in flat or down markets.
3 This hypothetical example reflects a 7-year withdrawal charge period where no withdrawals were taken. Rates are subject to change. Please see the current rate sheet for Protected Growth Benefit rates. The Protected Growth Benefit Rate is currently 26.25% for the 7-year product and 17.5% for the 5-year product.
4 Protected Growth Benefit is available only on Power Index 5 Plus and Power Index Plus and is not available in California or New York.
5 Preset allocation options are available only on Power Index 5 Plus, Power Index Plus, Power Index Plus Income and AG Choice 10 and are not available in New York.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260727837432/en/
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Agilon Health, Inc. (NYSE: AGL) (“Agilon”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/agilon-health/ Recently a securities fraud complaint was filed against Agilon on behalf of certain investors who purchased shares of the company's stock between April 15, 2021 and February 27, 2024. According to the complaint, during that.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that its Accountable Care Organizations (ACOs) achieved $229 million in gross savings (13.6% gross savings rate), including $54 million savings in the Medicare Trust Fund, during the 2024 performance year of the ACO Realizing Equity, Access and Community Health (ACO REACH) model. agilon's eight REACH ACOs operate under full risk, a.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the second quarter 2026 after market close on Wednesday, August 5, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 439-1904 for U.S. participants and +1 (585) 542-9983 for international participants and refe.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Agilon Health (AGL - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Agilon Health currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for AGL that show why this senior-focused health care company shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For AGL, shares are up 0.79% over the past week while the Zacks Medical Services industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 18.68% compares favorably with the industry's 0.19% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Agilon Health have risen 898.6%, and are up 85.71% in the last year. In comparison, the S&P 500 has only moved 11.94% and 22.09%, respectively.
Investors should also take note of AGL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now AGL is averaging 270,241 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with AGL.
Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost AGL's consensus estimate, increasing from -$5.30 to -$1.80 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that AGL is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Agilon Health on your short list.
Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
Agilon Health (AGL - Free Report) is one of the several great candidates that made it through the screen. While there are numerous reasons why this stock is a great choice, here are the most vital ones:
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 18.7%, the stock of this senior-focused health care company is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. AGL meets this criterion too, as the stock gained 898.6% over the past 12 weeks.
Moreover, the momentum for AGL is fast paced, as the stock currently has a beta of 3.02. This indicates that the stock moves 202% higher than the market in either direction.
Given this price performance, it is no surprise that AGL has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped AGL earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, AGL is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. AGL is currently trading at 0.31 times its sales. In other words, investors need to pay only 31 cents for each dollar of sales.
So, AGL appears to have plenty of room to run, and that too at a fast pace.
In addition to AGL, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
Investors in agilon health, inc. (AGL - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 17, 2026 $70 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for agilon health shares, but what is the fundamental picture for the company? Currently, agilon health is a Zacks Rank #3 (Hold) in the Medical Services industry that ranks in the Top 38% of our Zacks Industry Rank. Over the last 60 days, three analysts have increased their earnings estimates for the current quarter, while none have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of $1.52 per share to earnings of 6 cents in that period.
Given the way analysts feel about agilon health right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the first quarter 2026 after market close on Wednesday, May 6, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for international participants and referenc.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of agilon health, inc. (NYSE: AGL) breached their fiduciary duties to shareholders.
If you currently own agilon stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Agilon Health (NYSE:AGL – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Risk and Volatility Agilon Health has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
Earnings & Valuation This table compares Agilon Health and iSpecimen”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agilon Health $5.93 billion 0.06 -$391.35 million ($23.75) -0.95 iSpecimen $1.93 million 1.68 -$10.49 million ($2.35) -0.05 iSpecimen has lower revenue, but higher earnings than Agilon Health. Agilon Health is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership 13.6% of iSpecimen shares are owned by institutional investors. 2.3% of Agilon Health shares are owned by insiders. Comparatively, 12.2% of iSpecimen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations This is a breakdown of current recommendations and price targets for Agilon Health and iSpecimen, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agilon Health 2 10 3 0 2.07 iSpecimen 1 0 0 0 1.00 Agilon Health currently has a consensus price target of $40.23, indicating a potential upside of 77.91%. Given Agilon Health’s stronger consensus rating and higher possible upside, research analysts clearly believe Agilon Health is more favorable than iSpecimen.
Profitability This table compares Agilon Health and iSpecimen’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Agilon Health -6.60% -120.82% -24.89% iSpecimen -543.37% -496.31% -133.56% About Agilon Health (Get Free Report)
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About iSpecimen (Get Free Report)
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEJ-Long Group (NASDAQ:JL) and Crocs (NASDAQ:CROX) Financial Survey
NEXT HEADLINE »Financial Survey: Saratoga Investment (NYSE:SAR) versus Gladstone Investment (NASDAQ:GAIN)
agilon health is rated a cautious 'Hold' as management executes a strategic downsizing to address persistent losses. Recent exits from underperforming markets and partnerships are expected to improve medical margin from -$56.6 million in 2025 to $325 million in 2026. Despite revenue and membership declines, AGL guides for near break-even EBITDA in 2026, a significant improvement from -$296.2 million prior.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Agilon Health (AGL - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Agilon Health is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AGL's full-year earnings has moved 40.2% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AGL has returned about 64.4% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 5.5% on average. This shows that Agilon Health is outperforming its peers so far this year.
Another stock in the Medical sector, Caribou Biosciences, Inc. (CRBU - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 44%.
For Caribou Biosciences, Inc., the consensus EPS estimate for the current year has increased 9.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Agilon Health belongs to the Medical Services industry, a group that includes 62 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 9.5% so far this year, so AGL is performing better in this area.
Caribou Biosciences, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 436-stock industry is ranked #92. The industry has moved +2.5% so far this year.
Agilon Health and Caribou Biosciences, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL) (the “Company”), the trusted partner empowering physicians to transform health care in our communities, today announced the appointment of Tim O'Rourke as Chief Executive Officer and a member of the Company's Board of Directors, effective May 7. He succeeds Ronald A. Williams, who has served as Executive Chairman since August 2025 and will continue as Chairman of the Board. The appointment comes as agilon enters a new phase following.
An AGL Energy logo is visible above their offices in Adelaide, Australia, September 18, 2025. REUTERS/Hollie Adams. Purchase Licensing Rights, opens new tab
SummaryCompaniesCompany lifts its fiscal 2026 operating earnings forecastSees pressure from softer market conditions in FY27Sees Liddell battery fully operational by year-endMay 6 (Reuters) - Australia's AGL Energy (AGL.AX), opens new tab raised the lower end of its annual profit forecast range on Wednesday, banking on better plant performance and tighter cost control, and said it is well placed for the next three months during the global fuel crisis.
Australia's top power producer now expects 2026 underlying net profit after tax between A$610 million and A$680 million ($437.98 million and $488.24 million), compared with the A$580 million to A$680 million previously expected and a Visible Alpha consensus of A$646.3 million.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
It also raised its annual operating earnings forecast to between A$2.06 billion and A$2.18 billion, compared with the A$2.02 billion to A$2.18 billion previously expected and the Visible Alpha estimate of A$2.14 billion.
AGL shares rose 0.42% on Wednesday while the S&P/ASX200 (.AXJO), opens new tab was up 1.3%.
Amid diesel supply disruptions in Australia triggered by the Middle East conflict, Chief Executive Damien Nicks said AGL was well placed with fuel supplies and its Bayswater power station had 90 days worth of diesel on hand.
The plant uses diesel in start-up and shutdown processes for its coal-fired units and for heavy machinery and trucks.
"We're very comfortable with the supplies we have. We can continue to get access to diesel," he told the Macquarie Australia Conference in Sydney.
"We believe we'll continue to get it as an essential services provider."
AGL attributed the upgraded forecast to improved plant availability and flexibility, a good showing by its thermal generation fleet, improved customer markets performance and disciplined cost management.
While the broader sector faces headwinds from elevated fuel costs and geopolitical risks, the upgrade highlights that well-run operators with diversified assets and strong cost control can still navigate this environment successfully, said Tim Waterer, chief market analyst at KCM Trade.
"It's an encouraging sign for the Australian energy sector," Waterer said.
AGL, Australia's largest corporate carbon emitter, had said in February that it was targeting A$50 million in sustainable net operating cost reductions in FY27.
The company on Wednesday warned of pressure from softer domestic and global market conditions in fiscal 2027, along with declining wholesale prices in select locations.
AGL will take into account these factors in its 2027 forecast, to be presented at its annual results in August, together with the full-year contribution from its Liddell Battery project and cost-saving measures.
The project, a 500-MW grid-scale battery in New South Wales, is expected to be fully operational by June.
($1 = 1.3928 Australian dollars)
Reporting by Scott Murdoch in Sydney, Sneha Kumar in Bengaluru, additional reporting by Roshan Thomas; Editing by Jonathan Ananda and Subhranshu Sahu
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Scott Murdoch has been a journalist for more than two decades working for Thomson Reuters and News Corp in Australia. He has specialised in financial journalism for most of his career and covers the Australian financial services sector and superannuation. He is based in Sydney.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the first quarter ended March 31, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities. We.
Agilon Health (AGL - Free Report) reported $1.42 billion in revenue for the quarter ended March 2026, representing a year-over-year decline of 7.3%. EPS of $1.80 for the same period compares to $0 a year ago.
The reported revenue represents a surprise of +3.28% over the Zacks Consensus Estimate of $1.38 billion. With the consensus EPS estimate being $1.13, the EPS surprise was +58.73%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Avg. Medicare Advantage Members: 424,000 versus 473,750 estimated by two analysts on average.Revenues- Medical services: $1.42 billion versus the three-analyst average estimate of $1.37 billion. The reported number represents a year-over-year change of -7.3%.Revenues- Other operating: $1.91 million compared to the $2.83 million average estimate based on three analysts. The reported number represents a change of -34.2% year over year.View all Key Company Metrics for Agilon here>>>
Shares of Agilon have returned +61.2% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Agilon Health (AGL - Free Report) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +58.73%. A quarter ago, it was expected that this senior-focused health care company would post a loss of $6.75 per share when it actually produced a loss of $11.5, delivering a surprise of -70.37%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Agilon, which belongs to the Zacks Medical Services industry, posted revenues of $1.42 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.28%. This compares to year-ago revenues of $1.53 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Agilon shares have added about 55.3% since the beginning of the year versus the S&P 500's gain of 6%.
What's Next for Agilon?While Agilon has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Agilon was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.44 on $1.33 billion in revenues for the coming quarter and -$6.36 on $5.45 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Ascend Wellness Holdings, Inc. (AAWH - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 13.
This company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of -44.4%. The consensus EPS estimate for the quarter has been revised 3.9% higher over the last 30 days to the current level.
Ascend Wellness Holdings, Inc.'s revenues are expected to be $114.2 million, down 10.8% from the year-ago quarter.
Agilon Health Inc. (NYSE:AGL) shares are soaring on Thursday as the company recently announced an increase in its full-year 2026 guidance. The company operates and manages a network of independent physicians.
Agilon Health Shares Rise After Guidance IncreaseThe company announced results that reflect disciplined execution and progress against its strategic priorities.
Agilon Health reported first-quarter earnings of $1.80 per share, beating the consensus of $1.31.
Sales reached $1.42 billion, surpassing the Wall Street estimate of $1.38 billion.
Revenues fell 7% year over year, reflecting lower year-over-year membership partially offset by improved pricing, contract economics, and burden of illness performance.
Membership Declines While Margins ImproveTotal members on the Agilon platform decreased to 536,000 as of March 31, 2026, including 426,000 Medicare Advantage members and 110,000 ACO model beneficiaries.
Medical margin was $149 million, up from $128 million a year ago. Medical margin includes the cost trend for Medicare Advantage members reserved at 7.4%.
Adjusted EBITDA was $54 million, up from $21 million a year ago.
We are seeing early returns from investments in data and technology, clinical execution, and operating discipline,” said Ronald Williams, Executive Chairman.
Agilon Health Raises 2026 Revenue Outlook“We are also strengthening our Total Care Model—expanding clinical pathways, improving quality, and deepening payor alignment—positioning us for more predictable outcomes and sustained margin expansion. We remain confident in our 2026 outlook and long-term growth trajectory,” Williams further added.
Agilon Health expects second-quarter sales of $1.44 billion-$1.48 billion compared to the consensus of $1.34 billion.
The company raised its fiscal 2026 sales guidance from $5.41 billion-$5.58 billion to $5.68 billion-$5.81 billion, versus the consensus of $5.45 billion.
William Blair notes it was a good start to 2026, and ongoing clinical, cost-cutting, and operational initiatives appear to be driving a solid turnaround at the company.
How Agilon Health (AGL) Ranks On MomentumBelow is the Benzinga Edge scorecard for Agilon Health, highlighting its strengths and weaknesses compared to the broader market:
Momentum: Neutral (Score: 58.56) — Stock is showing moderate performance indicators. The Verdict: Agilon Health’s Benzinga Edge signal reveals a momentum-driven story, suggesting that while the stock has shown some recovery, it remains to be seen if this upward trend can be sustained in the long term.
AGL Price Action: Agilon Health shares were up 99.89% at $55.67 at the time of publication on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
Agilon Health shares rose sharply after the healthcare company posted better-than-expected first-quarter results and boosted its full-year guidance. (Dreamstime)
Shares of Agilon Health headed for their best day on record after the beleaguered healthcare company posted better-than-expected earnings, coupled with an outpouring of glowing commentary from analysts.
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Agilon Health (AGL - Free Report) is one of them. Here are the key reasons why this stock is a great candidate.
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 185.1%, the stock of this senior-focused health care company is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. AGL meets this criterion too, as the stock gained 500.9% over the past 12 weeks.
Moreover, the momentum for AGL is fast paced, as the stock currently has a beta of 2.29. This indicates that the stock moves 129% higher than the market in either direction.
Given this price performance, it is no surprise that AGL has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped AGL earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, AGL is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. AGL is currently trading at 0.16 times its sales. In other words, investors need to pay only 16 cents for each dollar of sales.
So, AGL appears to have plenty of room to run, and that too at a fast pace.
In addition to AGL, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Agilon Health (AGL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agilon Health is one of 888 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AGL's full-year earnings has moved 47.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AGL has returned about 215% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -8.2% on a year-to-date basis. This shows that Agilon Health is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Amarin (AMRN - Free Report) . The stock is up 7.9% year-to-date.
The consensus estimate for Amarin's current year EPS has increased 12.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Agilon Health belongs to the Medical Services industry, a group that includes 63 individual companies and currently sits at #98 in the Zacks Industry Rank. Stocks in this group have lost about 11% so far this year, so AGL is performing better this group in terms of year-to-date returns.
In contrast, Amarin falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 432 stocks and is ranked #142. Since the beginning of the year, the industry has moved -1.8%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Agilon Health and Amarin as they could maintain their solid performance.
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Agilon Health (AGL - Free Report) is one of them. Here are the key reasons why this stock is a great candidate.
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 205.6%, the stock of this senior-focused health care company is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. AGL meets this criterion too, as the stock gained 501.1% over the past 12 weeks.
Moreover, the momentum for AGL is fast paced, as the stock currently has a beta of 2.29. This indicates that the stock moves 129% higher than the market in either direction.
Given this price performance, it is no surprise that AGL has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped AGL earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, AGL is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. AGL is currently trading at 0.24 times its sales. In other words, investors need to pay only 24 cents for each dollar of sales.
So, AGL appears to have plenty of room to run, and that too at a fast pace.
In addition to AGL, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Agilon Health (AGL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Agilon Health is a member of the Medical sector. This group includes 884 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AGL's full-year earnings has moved 62.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AGL has gained about 395.3% so far this year. Meanwhile, stocks in the Medical group have lost about 6% on average. This means that Agilon Health is outperforming the sector as a whole this year.
Another stock in the Medical sector, Humacyte, Inc. (HUMA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.6%.
In Humacyte, Inc.'s case, the consensus EPS estimate for the current year increased 28% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Agilon Health is a member of the Medical Services industry, which includes 62 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 11.6% so far this year, so AGL is performing better in this area.
Humacyte, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 430-stock industry is ranked #142. The industry has moved -0.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Agilon Health and Humacyte, Inc. as they attempt to continue their solid performance.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Agilon Health (AGL - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Agilon Health currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for AGL that show why this senior-focused health care company shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For AGL, shares are up 5.7% over the past week while the Zacks Medical Services industry is up 0.93% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 223.52% compares favorably with the industry's 1.25% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of Agilon Health have increased 416.71% over the past quarter, and have gained 53.58% in the last year. In comparison, the S&P 500 has only moved 9.66% and 28.33%, respectively.
Investors should also take note of AGL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now AGL is averaging 581,877 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with AGL.
Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost AGL's consensus estimate, increasing from -$6.38 to -$3.78 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that AGL is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Agilon Health on your short list.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that members of its management team will participate in investor meetings and industry discussions at the following conferences:
Truist Securities Healthcare Disruptors & Digital Health Conference on Tuesday, June 23, 2026 in New York. Management will participate in an ACO Model panel discussion at 1:50pm ET and conduct one-on-one meetings with investors. Citizens Healthcare Services Forum on Thursday, June 25, 2026 in Boston. Management will conduct one-on-one meetings with investors. Due to the format of these events, meetings will not be available for webcasting. Interested investors and other parties may contact the conference organizers or agilon health’s Investor Relations team for registration information.
About agilon health
agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of approximately 2,200 primary care physicians (PCPs) that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in approximately 30 diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information visit www.agilonhealth.com and connect with us on LinkedIn.
